Business Wire

Palantir Awarded Australian Transaction Reports and Analysis Centre (AUSTRAC) Renewal to Support Financial Criminal Investigations

Share

Palantir Technologies Inc. (NYSE: PLTR) today announced that the Australian Transaction Reports and Analysis Centre (AUSTRAC) renewed its partnership for the ongoing delivery of an intelligence data analysis platform to support the AUSTRAC mission of protecting Australia’s financial system from criminal abuse.

Since 2017, Palantir has partnered with AUSTRAC to optimise their use of financial data in support of criminal investigations. AUSTRAC builds resilience in the financial system and uses financial intelligence and regulation to disrupt money laundering, terrorism financing, and other serious crime.

AUSTRAC utilizes Palantir Technologies’ Gotham and Foundry software platforms to integrate and fuse large scale data across their enterprise, driving decisions and operational outcomes.

“We are proud to continue and expand our partnership with AUSTRAC and remain firmly committed to supporting their mission,” said Mike Kelly, Head of Palantir Australia. “AUSTRAC personnel are using Palantir’s software to identify national security threats and to detect and disrupt criminal networks - a real contribution to making Australia safer.”

About Palantir Technologies Inc.

Foundational software of tomorrow. Delivered today. Additional information is available at https://www.palantir.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir’s expectations regarding the amount and the terms of the contract and the expected benefits of our software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include our ability to meet the unique needs of our customer; the failure of our platforms to satisfy our customer or perform as desired; the frequency or severity of any software and implementation errors; our platforms’ reliability; and our customer’s ability to modify or terminate the contract. Additional information regarding these and other risks and uncertainties is included in the filings we make with the Securities and Exchange Commission from time to time. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lisa Gordon
media@palantir.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Climate Impact X Launches CIX Exchange to Level up Carbon Market Transparency, Certainty and Liquidity8.6.2023 02:00:00 CEST | Press release

Climate Impact X (CIX), a global marketplace, auctions house and exchange for trusted carbon credits, has successfully launched its spot trading platform, CIX Exchange, completing the company’s core solutions suite with three operational venues. Powered by Nasdaq's trading technology, CIX Exchange offers carbon market professionals a customised experience built on international best practices for platform stability, performance and governance. Users can efficiently discover market-driven prices, compare individual projects and trade standard contracts. To address industry calls for greater transparency and price certainty, CIX has introduced the first daily on-exchange liquidity window in the voluntary carbon market with firm bids and offers. This dedicated 30-minute pricing session pools all-day liquidity from Asia, Europe and Middle East to help sharpen benchmark prices and improve order depth for spot nature-based credits. By close of trading on 7 June 2023, bids and offers had conv

RevBio is Awarded a $2 Million Grant to Advance the Development of its Novel Dental Adhesive Bone Scaffold Product7.6.2023 23:12:00 CEST | Press release

RevBio, Inc., announced that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health (NIH). This funding (1R44DE032564-01) will allow the company to complete the pre-clinical research necessary to advance this product into the clinical stage of development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005794/en/ The current standard of care options for rebuilding deficient jawbone includes a variety of materials that require membranes and time consuming fixation devices. These products do not predictably maintain ridge volume which requires surgeons to undergo re-grafting in over 30% of clinical cases. TETRANITE eliminates the use of membranes and other fixation devices, when compared to the standard of care. Furthermore, TETRANITE resorbs fully while maintaining predict

IFF Names New President of Nourish and Introduces Leadership Structure Aligned to New Operating Model7.6.2023 22:18:00 CEST | Press release

IFF (NYSE: IFF) today announced that Yuvraj Arora, currently President, U.S. Categories for Kellogg North America, will join IFF as President, Nourish, effective June 19, 2023. Arora brings more than 25 years of multinational CPG experience to IFF’s Executive Leadership Team, mostly recently leading Kellogg’s $7 billion U.S. portfolio through a period of strong growth and portfolio transformation. IFF today also announced the leadership structure to support the transition to a new operating model as part of the company’s transformation strategy. The shift from its current divisional structure to three core end markets—Food and Beverage, Home and Personal Care, and Health—will provide greater customer intimacy and enhance cross-functional collaboration, allowing for enhanced execution, speed and streamlined delivery. IFF expects its new operating model to be in effect by the beginning of 2024. As President, Nourish, Arora, will lead IFF’s Food and Beverage categories when the operating

Vizgen Issues Open Letter to Customers and Researchers on 10x Genomics June 1, 2023 Lawsuit Announcement in Europe7.6.2023 21:00:00 CEST | Press release

Vizgen, Inc. (“Vizgen” or the “Company”), a life science leader dedicated to improving human health by visualizing single-cell spatial genomics information, today issued the below open letter to customers and researchers in response to 10x Genomics, Inc. (“10x”) filing a lawsuit on June 1, 2023 with the Unified Patent Court (“UPC”) in Europe. *** June 7, 2023 Dear Customers, Researchers and Friends of Vizgen: We are disappointed – though not surprised – that 10x has filed another lawsuit that attempts to undermine innovation, eliminate competition and intimidate both customers and industry peers. Although 10x’s UPC complaint is not yet available to us, we will keep you updated as we learn more. In the meantime, rest assured that we will vigorously defend our shared interests in all proceedings with the UPC, much like we have in the ongoing litigation in the U.S. District Court for the District of Delaware. In the Delaware case, we have gone on the offensive to assert our own countercla

Brenus Pharma announces its international Scientific Committee7.6.2023 18:00:00 CEST | Press release

Following the American Society of Clinical Oncology’s Annual Meeting, where Brenus’ innovative approach and promising preclinical results were featured in the abstract section “Treatment to Follow” 1, the company highlighted its international scientific committee. This committee gathering renowned international experts in immuno-oncology, immunotherapies, and novel-treatments is supporting Brenus’ scientific developments of the STCplatform pipeline in solid tumors and its first candidate, STC-1010 targeting colorectal cancer. The committee combined a total of over 1,700 internationally peer-reviewed articles and prestigious awards in the field: Pr François GHIRINGHELLIMD, PhD. Pr of Oncology – Head of “Cancer and adaptative immune response” INSERM, CGFL2, Dijon. (FR) Head of the Board Pr Ahmad AWADAMD, PhD. Pr of Oncology – Head of Oncology medicine Dept. Jules Bordet Institute-HUB, Brussel. (BE) & Board member Oncodistinct clinical and translational research network, ESMO3 active memb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom